The global retinal biologics market size was estimated to be USD 23.12 billion in 2023 and is expected to reach at USD 53.58 billion by 2034 with a CAGR of 7.94% during the forecast period 2024-2034. Increasing emphasis on developing novel drug products specifically for retinal diseases, growing prevalence of vision problems & diabetic retinopathy, rise in research & development efforts, increase in FDA approvals, surge in investments by major industry players, and rising introduction of innovative biologic products targeting retinal conditions are the key factors fuelling the growth of the market.
Rising introduction of innovative biologic products targeting retinal conditions is predicted to boost the market growth during the forecast period. Retinal biologics are generally described as large, intricate molecules derived from living cells or tissues. These products simplify the treatment of various diseases, making it both efficient and cost-effective. They represent technologically advanced materials that contribute to the cure of diseases. For instance, in June 2022, Biogen Inc. and Samsung Bioepis Co. Ltd. have revealed the launch of Ranibizumab-Nuna (Byooviz), a biosimilar referencing ranibizumab (Lucentis, Genentech), in the United States.
By drug class, VEGF-A Antagonist was the highest revenue-grossing segment in the global retinal biologics market in 2023 owing to the growing prevalence of vision problems and increasing product approvals. For instance, in January 2022, Genentech, part of the Roche Group, has reported the approval of Vabysmo (faricimab-svoa) by the U.S. Food and Drug Administration (FDA) for treating wet or neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, TNF-a Inhibitor is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of retinal diseases such as diabetic retinopathy and surge in launch of novel biologic products.
By indication, macular degeneration was the highest revenue-grossing segment in the global retinal biologics market in 2023 owing to the increasing drug launches for macular degeneration and the rising prevalence of macular degeneration. Additionally, diabetic retinopathy is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of diabetes, increasing research and development, and surge in regulatory approvals. For instance, in August 2023, The U.S. Food and Drug Administration (FDA) granted approval to Regeneron Pharmaceuticals, Inc. for the injection EYLEA HD, intended for treating diabetic retinopathy, wet age-related macular degeneration, and diabetic macular edema.
By distribution channels, hospital pharmacies was the highest revenue-grossing segment in the global retinal biologics market in 2023 owing to the advantages it offers include enhanced access to patients' medical records and the availability of a diverse array of medications, including those designed for specialized purposes that may be prescribed exclusively within a controlled medical setting. For instance, in October 2023, Coherus BioSciences, Inc. has disclosed that the sales of CIMERLI (ranibizumab-eqrn) to retinal specialists have surpassed 100,000 doses since its commercial launch. CIMERLI stands out as the initial and sole FDA-approved biosimilar interchangeable with Lucentis for all approved indications. Additionally, retail pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the surge in number of prescriptions, growing number of patients suffering from retinal diseases.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of retinal diseases, increasing strategic initiatives by key market players, and growing approvals by regulatory authorities. For instance, in December 2023, Formycon AG, Polpharma Biologics Group BV, Bioeq AG, and Teva Canada Ltd. collectively declare that Health Canada has issued the "Notice of Compliance" (NOC) for Ranopto (Ranibizumab), a biosimilar to Lucentis, designed for treating various severe retinal diseases in Canada. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing burden of the diabetic population, rise in research and development activities, and increasing product launches. For instance, in December 2023, India-based Enzene Biosciences has unveiled the introduction of ranibizumab, a biosimilar to Lucentis, marketed under the name Accentrix in India.
Rising introduction of innovative biologic products targeting retinal conditions is predicted to boost the market growth during the forecast period. Retinal biologics are generally described as large, intricate molecules derived from living cells or tissues. These products simplify the treatment of various diseases, making it both efficient and cost-effective. They represent technologically advanced materials that contribute to the cure of diseases. For instance, in June 2022, Biogen Inc. and Samsung Bioepis Co. Ltd. have revealed the launch of Ranibizumab-Nuna (Byooviz), a biosimilar referencing ranibizumab (Lucentis, Genentech), in the United States.
By drug class, VEGF-A Antagonist was the highest revenue-grossing segment in the global retinal biologics market in 2023 owing to the growing prevalence of vision problems and increasing product approvals. For instance, in January 2022, Genentech, part of the Roche Group, has reported the approval of Vabysmo (faricimab-svoa) by the U.S. Food and Drug Administration (FDA) for treating wet or neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, TNF-a Inhibitor is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of retinal diseases such as diabetic retinopathy and surge in launch of novel biologic products.
By indication, macular degeneration was the highest revenue-grossing segment in the global retinal biologics market in 2023 owing to the increasing drug launches for macular degeneration and the rising prevalence of macular degeneration. Additionally, diabetic retinopathy is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of diabetes, increasing research and development, and surge in regulatory approvals. For instance, in August 2023, The U.S. Food and Drug Administration (FDA) granted approval to Regeneron Pharmaceuticals, Inc. for the injection EYLEA HD, intended for treating diabetic retinopathy, wet age-related macular degeneration, and diabetic macular edema.
By distribution channels, hospital pharmacies was the highest revenue-grossing segment in the global retinal biologics market in 2023 owing to the advantages it offers include enhanced access to patients' medical records and the availability of a diverse array of medications, including those designed for specialized purposes that may be prescribed exclusively within a controlled medical setting. For instance, in October 2023, Coherus BioSciences, Inc. has disclosed that the sales of CIMERLI (ranibizumab-eqrn) to retinal specialists have surpassed 100,000 doses since its commercial launch. CIMERLI stands out as the initial and sole FDA-approved biosimilar interchangeable with Lucentis for all approved indications. Additionally, retail pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the surge in number of prescriptions, growing number of patients suffering from retinal diseases.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of retinal diseases, increasing strategic initiatives by key market players, and growing approvals by regulatory authorities. For instance, in December 2023, Formycon AG, Polpharma Biologics Group BV, Bioeq AG, and Teva Canada Ltd. collectively declare that Health Canada has issued the "Notice of Compliance" (NOC) for Ranopto (Ranibizumab), a biosimilar to Lucentis, designed for treating various severe retinal diseases in Canada. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing burden of the diabetic population, rise in research and development activities, and increasing product launches. For instance, in December 2023, India-based Enzene Biosciences has unveiled the introduction of ranibizumab, a biosimilar to Lucentis, marketed under the name Accentrix in India.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Retinal Biologics Market Report 2023 - 2034
Retinal Biologics Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- VEGF-A Antagonist
- TNF-a Inhibitor
Retinal Biologics Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Diabetic Retinopathy
- Macular Degeneration
- Uveitis
- Others
Retinal Biologics Market Analysis & Forecast by Distribution Channels 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Retinal Biologics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Retinal Biologics Market: Drug Class Estimates & Trend Analysis
8. Retinal Biologics Market: Indication Estimates & Trend Analysis
9. Retinal Biologics Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Retinal Biologics Market
12. Europe Retinal Biologics Market
13. Asia Pacific Retinal Biologics Market
14. Latin America Retinal Biologics Market
15. MEA Retinal Biologics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- Allergan
- Oxurion NV
- MeiraGTx Limited
- F-Hoffman La Roche Ltd.
- AbbVie Inc.
- OncoGene Pharmaceuticals
- Janssen Pharmaceuticals (Johnson & Johnson)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 23.12 Billion |
| Forecasted Market Value ( USD | $ 53.58 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
